Home Your basket
• Unilateral endolymphatic ...
   Price 10.50 €
• Botulinum toxin in the lo...
   Price 14.00 €
• Cleft palate and otitis m...
   Price 10.50 €
• Audiological comparison b...
   Price 14.00 €
• Intra-orbital infected cy...
   Price 5.50 €
• Osteointegrated cranio-fa...
   Price 10.50 €
• Nasal cutaneous cryptococ...
   Price 5.50 €
• Comparative results of ty...
   Price 10.50 €
• Fistulisation of a tuberc...
   Price 5.50 €
• Recent advances in surger...
   Price 5.50 €
• Distortion product otoaco...
   Price 10.50 €
• Prospective evaluation of...
   Price 10.50 €
• Conference : Medicine of ...
   Price 5.50 €
• Use of instrumental vocal...
   Price 10.50 €
• Pharyngeal pouch surgery ...
   Price 5.50 €
• Stapedotomy and anatomica...
   Price 5.50 €
• Protruding ears...
   Price 8.50 €
• The outcome of treatments...
   Price 10.50 €
• Non-traumatic nasal septa...
   Price 8.50 €
• Analysis of the possibili...
   Price 8.50 €
• Validity of cervical ausc...
   Price 12.00 €
• Validation of a self-asse...
   Price 10.50 €
• Otolaryngological aspects...
   Price 8.50 €
• A survey of current wound...
   Price 5.50 €
• Notes on voice and speech...
   Price 8.50 €
• Hearing aid : practical a...
   Price 8.50 €
• Total ossicular reconstru...
   Price 10.50 €
• Metastatic melanoma to th...
   Price 5.50 €
• Saddle nose surgery: Long...
   Price 10.50 €
• Bilateral facial nerve pa...
   Price 5.50 €
• Prevalence of and risk fa...
   Price 10.50 €
• Vertigo: progress and pra...
   Price 8.50 €
• Recurrences of pleomorphi...
   Price 10.50 €
• Management of labial inco...
   Price 10.50 €
• Solitary myofibroma of th...
   Price 5.50 €

Total Order 307.00 €

contents
2019
   N# 1 |
2018
   N# 1 | 2 | 3 | 4 | 5 |
2017
   N# 1 | 2 | 3 | 4 | 5 |
2016
   N# 1 | 2 | 3 | 4 | 5 |
2015
   N# 1 | 2 | 3 | 4 | 5 |
2014
   N# 1 | 2 | 3 | 4 | 5 |
2013
   N# 1 | 2 | 3 | 4 | 5 |
2012
   N# 1 | 2 | 3 | 4 | 5 |
2011
   N# 1 | 2 | 3 | 4 | 5 |
2010
   N# 1 | 2 | 3 | 4 | 5 |
2009
   N# 1 | 2 | 3 | 4 | 5 |
2008
   N# 1 | 2 | 3 | 4 | 5 |
2007
   N# 1 | 2 | 3 | 4 | 5 |
2006
   N# 1 | 2 | 3 | 4 | 5 |
2005
   N# | 1 | 2 | 3 | 4 | 5 |
2004
   N# 1 | 2 | 3 | 4 | 5 |
2003
   N# 1 | 2 | 3 | 4 | 5 |
2002
   N# 1 | 2 | 3 | 4 | 5 |
2001
   N# 1 | 2 | 3 | 4 | 5 |
2000
   N# | 1 | 2 | 3 | 4 | 5 |
1999
   N# 1 | 2 | 3 | 4 | 5 |
1998
   N# 1 | 2 | 3 | 5 |
1997
   N# 1 | 2 | 3 | 4 | 5 |
1996
   N# 4 | 5 |

Click on the number of the review to see the content
Teaching bulletin CME
List of all teaching bulletins CME.
Editor reading committee
Editor reading committee.
To publish...
Instructions for authors
Archives Press and Books
Select of books and press articles.
Mailing list
News information letter.
Subscription prices


If you wish to adjust the size of the displayed characters, click in the high menu on "Your account" and choose the desired size.



  Contents > Previous page > Article detail print Order
o Issue N# 4 - 2008 o

OTONEUROLOGY

Disability in patients with Menière’s disease following the use of two different treatment modalities: Betahistine and intratympanic gentamicin


Authors : Enrique-Gonzalez A, Sánchez-Ferrándiz N, Pérez-Fernández N. (Pamplona)

Ref. : Rev Laryngol Otol Rhinol. 2008;129,4:249-254.

Article published in english
Downloadable PDF document english



Summary : Objective: The objective of this study was to assess the level of residual disability and handicap in patients with Menière’s disease (MD) that were free of new vertigo spells 2 years after having been administered treatment with either oral medication or with intratympanic gentamcin. Setting: University hospital. Tertiary medical center. Material and method: 40 patients with MD were included in this study, of which 20 were treated with oral medication (betahistine) and 20 with intratympanic gentamicin; intratympanic gentamicin was for patients considered failures for the oral medication treatment. All of them are free of new vertigo in the 16-24 month period after beginning the treatment. They were matched by age and disease duration. Disability and handicap were assessed with conventional questionnaires at the time of inclusion and 2 years after beginning oral medication or ended the intratympanic gentamicin treatment. According to the treatment two groups were created: oral medication treatment and intratympanic gentamicin treatment. Results: The amount of disability before treatment was higher in patients treated with intratympanic gentamicin than in those under oral medication; However, after treatment when no more vertigo spells takes place, this disability is significantly reduced and becomes similar for both groups of patients. In patients treated with oral medication the items reflecting the intensity of vertigo spell, the impact of vertigo in daily activities, the perception of quality of life and level of somatization do not show a significant reduction. Conclusion: The number or frequency of vertigo spells are very relevant for the process of disability and handicap of patients with MD when that is low or when oral medication is sufficient to eliminate vertigo spells. However when that number is high and the only possibility to arrest those vertigo spells is the use of intratympanic gentamicin, fear of vertigo must be considered as an associated problem for the patient.

Price : 10.50 €      order
|


Subscribe online - Pay by credit card!


© Copyright 1999-2024 - Revue de Laryngologie   Réalisation - Hébergement ELIDEE